EUVIMEDEUVIMED entdecken
Crossref

Pulmonary pharmacokinetics, epithelial lining fluid exposure and PK/PD characterization of the novel pleuromutilin derivative APTM against methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae in mice

Weicong Yang iD, Luoju Wang, Lei Yan, Haibo Wang, Xiaona Ma, Taiming Lv, Huanzhong Ding

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Weicong Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Veterinary Drug Residue Standard Laboratory, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Diterpenes, Streptococcus pneumoniae, Methicillin-Resistant Staphylococcus aureus. Die Arbeit nennt 17 Literaturangaben. Gefördert von: College of Veterinary Medicine, South China Agricultural University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To characterize pulmonary pharmacokinetics (PK), epithelial lining fluid (ELF) exposure, antibacterial activity and preliminary PK/pharmacodynamic (PK/PD) relationships of the pleuromutilin derivative APTM in neutropenic murine lung infection models.

Methods

Plasma PK and ELF exposure were assessed after a single oral dose in healthy mice. Minimum inhibitory concentrations (MICs) and in vitro time-kill activity were determined against methicillin-resistant Staphylococcus aureus USA300 and Streptococcus pneumoniae ATCC 49619. In vivo efficacy was assessed in neutropenic murine lung infection models. The ratio of the 24 h area under the plasma concentration–time curve to MIC (AUC0–24h/MIC) and the ratio of maximum plasma concentration to MIC (Cmax/MIC) were evaluated as candidate indices using Sigmoid Imax models.

Results

Plasma exposure increased approximately linearly over 10–150 mg/kg. Mean total ELF/plasma ratios were 1.21 for Cmax and 2.05 for the area under the concentration–time curve from time zero to infinity (AUC0–∞). MICs were 0.25 mg/L for USA300 and 0.5 mg/L for ATCC 49619. Relative to the 2 h baseline, maximal mean reductions in pulmonary bacterial burden at 150 mg/kg were 3.39 log10 cfu/mL for USA300 and 1.63 log10 cfu/mL for ATCC 49619. Under the single every-12-h (q12h) regimen, AUC0–24h/MIC showed a stronger association with antibacterial efficacy than Cmax/MIC.

Conclusions

APTM achieved measurable pulmonary exposure and antibacterial activity in murine lung infection models. AUC0–24h/MIC was the best-performing exposure metric among those evaluated under the present conditions; it should not be interpreted as a definitive PK/PD driver. These exploratory, isolate-specific findings support further PK/PD studies of APTM for respiratory infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDiterpenesStreptococcus pneumoniaeMethicillin-Resistant Staphylococcus aureusLungAnimalsPleuromutilinsPolycyclic CompoundsMiceMicrobial Sensitivity TestsDisease Models, AnimalFemalePlasmaMaleAdministration, Oral

Substanzen

PleuromutilinsAnti-Bacterial AgentsPolycyclic CompoundsDiterpenes

Autor:innen und Institutionen

  • National Veterinary Drug Residue Standard Laboratory, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
  • National Veterinary Drug Safety Evaluation (Environmental Assessment) Laboratory, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
  • Institute of R&D, Shandong Qilu-Kingphar Pharmaceutical Co., Ltd., Pingyin County, Jinan, China.

ORCID-Profile: Weicong Yang

Förderung

  • College of Veterinary Medicine
  • South China Agricultural University

Zitieren

APA

Yang, W., Wang, L., Yan, L., Wang, H., Ma, X., Lv, T., & Ding, H. (2026). Pulmonary pharmacokinetics, epithelial lining fluid exposure and PK/PD characterization of the novel pleuromutilin derivative APTM against methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae in mice. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag306

Vancouver

Yang W, Wang L, Yan L, Wang H, Ma X, Lv T, et al. Pulmonary pharmacokinetics, epithelial lining fluid exposure and PK/PD characterization of the novel pleuromutilin derivative APTM against methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae in mice. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag306

BibTeX
@article{Yang2026,
  author = {Yang, Weicong and Wang, Luoju and Yan, Lei and Wang, Haibo and Ma, Xiaona and Lv, Taiming and Ding, Huanzhong},
  title = {Pulmonary pharmacokinetics, epithelial lining fluid exposure and PK/PD characterization of the novel pleuromutilin derivative APTM against methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae in mice},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag306}
}
Kostenlos starten →